{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:01:58Z","timestamp":1794333718797,"version":"4.9.0"},"reference-count":96,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1136\/bjophthalmol-2014-305131","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T03:29:39Z","timestamp":1404358179000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":129,"title":["Myopic choroidal neovascularisation: current concepts and update on clinical management"],"prefix":"10.1136","volume":"99","author":[{"given":"Tien Y","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno-Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Leveziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Gon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2014-305131-1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-94-009-8662-6_31","article-title":"Natural history of Fuchs\u2019 spot: a long-term follow-up study","volume":"28","author":"Fried","year":"1981","journal-title":"Doc Ophthal Proc Series"},{"key":"key-10.1136\/bjophthalmol-2014-305131-3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","article-title":"Visual prognosis of disciform degeneration in myopia","volume":"90","author":"Hampton","year":"1983","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"key-10.1136\/bjophthalmol-2014-305131-5","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1167\/iovs.12-9538","article-title":"Genetic factors for choroidal neovascularization associated with high myopia","volume":"53","author":"Leveziel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-305131-6","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-305131-7","first-page":"3287","article-title":"Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro","volume":"40","author":"Seko","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-305131-8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bmj.324.7347.1195","article-title":"Myopia","volume":"324","author":"Fredrick","year":"2002","journal-title":"BMJ"},{"key":"key-10.1136\/bjophthalmol-2014-305131-11","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1167\/iovs.11-9405","article-title":"Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes","volume":"53","author":"Akagi-Kurashige","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-305131-12","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1167\/iovs.13-12280","article-title":"Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes","volume":"54","author":"Miyake","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-305131-13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bjo.2009.163535","article-title":"Choroidal filling delay in choroidal neovascularisation due to pathological myopia","volume":"94","author":"Wakabayashi","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9394(14)71034-7","article-title":"Macular complications associated with posterior staphyloma","volume":"123","author":"Steidl","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","article-title":"Choroidal neovascularisation in pathological myopia: an update in management","volume":"89","author":"Chan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00055735-200106000-00014","article-title":"Natural history of choroidal neovascularization in high myopia","volume":"12","author":"Miller","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.survophthal.2007.12.004","article-title":"Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment","volume":"53","author":"Soubrane","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\u2014VIP report no. 1","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12348-011-0054-6","article-title":"Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography","volume":"2","author":"Channa","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"key-10.1136\/bjophthalmol-2014-305131-20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/IAE.0b013e318203c1ef","article-title":"Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis","volume":"31","author":"Vance","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0002-9394(84)90243-5","article-title":"Punctate inner choroidopathy","volume":"98","author":"Watzke","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000339893","article-title":"Myopic maculopathy: a review","volume":"228","author":"Silva","year":"2012","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305131-23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ajo.2012.11.021","article-title":"Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization","volume":"155","author":"Leveziel","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-25","doi-asserted-by":"crossref","first-page":"e47237","DOI":"10.1371\/journal.pone.0047237","article-title":"Parapapillary atrophy: histological gamma zone and delta zone","volume":"7","author":"Jonas","year":"2012","journal-title":"PLoS One"},{"key":"key-10.1136\/bjophthalmol-2014-305131-26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s00417-006-0324-4","article-title":"Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia","volume":"244","author":"Kojima","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","article-title":"Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups","volume":"109","author":"Yoshida","year":"2002","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","article-title":"Characteristics of patients with a favorable natural course of myopic choroidal neovascularization","volume":"243","author":"Hayashi","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(81)90170-7","article-title":"Pathologic myopia and choroidal neovascularization","volume":"91","author":"Hotchkiss","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-31","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0161-6420(99)90484-0","article-title":"Visual acuity outcomes of patients 50\u2005years of age and older with high myopia and untreated choroidal neovascularization","volume":"106","author":"Tabandeh","year":"1999","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/112067210201200207","article-title":"Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes","volume":"12","author":"Ruiz-Moreno","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0002-9394(02)01883-4","article-title":"Pathologic myopia: where are we now?","volume":"134","author":"Tano","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-34","first-page":"CD004765","article-title":"Laser photocoagulation for choroidal neovascularisation in pathologic myopia","author":"Virgili","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/bjophthalmol-2014-305131-35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/112067219700700401","article-title":"Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment","volume":"7","author":"Secretan","year":"1997","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10792-012-9532-6","article-title":"Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors","volume":"32","author":"Altan","year":"2012","journal-title":"Int Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/bjo.2006.103606","article-title":"Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/IAE.0b013e31804b1e6f","article-title":"Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up","volume":"27","author":"Chen","year":"2007","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/01.iae.0000244260.52901.2e","article-title":"Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study","volume":"26","author":"Costa","year":"2006","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ajo.2010.06.046","article-title":"Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"151","author":"Hayashi","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajo.2007.10.032","article-title":"Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls","volume":"145","author":"Hayashi","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ajo.2005.03.050","article-title":"Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy","volume":"140","author":"Krebs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bjo.2004.041624","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2\u2005year follow up","volume":"88","author":"Lam","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bjo.87.2.173","article-title":"Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation","volume":"87","author":"Montero","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.iae.0000244256.60524.c0","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study","volume":"26","author":"Pece","year":"2006","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000322362","article-title":"A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia","volume":"225","author":"Pece","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305131-47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ajo.2006.11.037","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study","volume":"143","author":"Pece","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/IAE.0b013e3181ff9546","article-title":"Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5\u2005years of follow-up","volume":"31","author":"Coutinho","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/IAE.0b013e3182411cee","article-title":"Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia","volume":"32","author":"Giansanti","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00417-005-1147-4","article-title":"Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia","volume":"243","author":"Schnurrbusch","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-53","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":"Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study","volume":"27","author":"Tufail","year":"2013","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2014-305131-55","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. 2011. http:\/\/www.cebm.net\/index.aspx?o=5653 (accessed 13 Nov 2013)."},{"key":"key-10.1136\/bjophthalmol-2014-305131-56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajo.2010.09.021","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment","volume":"151","author":"Calvo-Gonzalez","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab","volume":"227","author":"Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305131-58","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"Lai","year":"2012","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2014-305131-59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/eye.2009.88","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results","volume":"23","author":"Mon\u00e9s","year":"2009","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2014-305131-60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results","volume":"30","author":"Silva","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/bjo.2009.174243","article-title":"Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study","volume":"95","author":"Vadala","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-62","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IAE.0b013e31819ed6bd","article-title":"Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","article-title":"Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization","volume":"30","author":"Yoon","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-66","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00417-010-1599-z","article-title":"Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses","volume":"249","author":"Ruiz-Moreno","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-68","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/IAE.0b013e3181e22659","article-title":"Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization","volume":"30","author":"Ruiz-Moreno","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-69","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":"Myopic choroidal neovascularization","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-70","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","article-title":"Intravitreal bevacizumab in myopic neovascular membranes: 24-month results","volume":"120","author":"Ruiz-Moreno","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-71","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/IAE.0b013e31821800a4","article-title":"Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series","volume":"31","author":"Iacono","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-72","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","article-title":"Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia","volume":"96","author":"Gharbiya","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-74","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-75","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"key-10.1136\/bjophthalmol-2014-305131-76","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-77","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000355569","article-title":"Cardiac issues of noncardiac drugs: the rising story of Avastin in age-related macular degeneration","volume":"231","author":"Cruess","year":"2014","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305131-79","unstructured":"US Food and Drug Administration. Potential use of Avastin in the treatment of wet age-related macular degeneration. 2011. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm270296.htm (accessed 11 Jul 2013)."},{"key":"key-10.1136\/bjophthalmol-2014-305131-80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/eye.2010.226","article-title":"Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"25","author":"Nakanishi","year":"2011","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2014-305131-81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archophthalmol.2009.408","article-title":"Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia","volume":"128","author":"Parodi","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-82","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajo.2008.11.020","article-title":"Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization","volume":"147","author":"Yodoi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-83","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":"Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome","volume":"97","author":"Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-84","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ophtha.2013.06.043","article-title":"Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia","volume":"121","author":"Miyake","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-86","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2014a randomized controlled trial","volume":"149","author":"Gharbiya","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-87","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"Iacono","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-88","unstructured":"ClinicalTrials.gov. VEGF trap-eye in choroidal neovascularization secondary to pathologic myopia (mCNV) (MYRROR). 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01249664?term=aflibercept+AND+myopia&rank=1 (accessed 1 Jul 2013)."},{"key":"key-10.1136\/bjophthalmol-2014-305131-89","unstructured":"Bayer HealthCare. Positive phase 3 results for VEGF Trap-Eye (intravitreal aflibercept) in myopic choroidal neovascularization (mCNV). 2013. http:\/\/press.healthcare.bayer.com\/en\/press\/auth\/news-details-page.php\/15070\/2013\u20130317 (accessed 25 Jul 2013)."},{"key":"key-10.1136\/bjophthalmol-2014-305131-90","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis","volume":"33","author":"Wang","year":"2013","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305131-91","unstructured":"Novartis. Lucentis summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000715\/WC500043546.pdf (accessed 13 Nov 2013)."},{"key":"key-10.1136\/bjophthalmol-2014-305131-92","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0161-6420(93)31471-5","article-title":"Prevalence of posterior vitreous detachment in high myopia","volume":"100","author":"Akiba","year":"1993","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305131-93","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/bjo.86.11.1269","article-title":"Macular hole and myopic refraction","volume":"86","author":"Kobayashi","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0002-9394(03)00144-2","article-title":"Peripheral retinal degenerations and the risk of retinal detachment","volume":"136","author":"Lewis","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-95","doi-asserted-by":"crossref","first-page":"175613","DOI":"10.1155\/2010\/175613","article-title":"Pathology of macular foveoschisis associated with degenerative myopia","volume":"2010","author":"Tang","year":"2010","journal-title":"J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305131-96","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10384-011-0034-2","article-title":"Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization","volume":"55","author":"Shimada","year":"2011","journal-title":"Jpn J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2014-305131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:47:41Z","timestamp":1601110061000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2014-305131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,18]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1136\/bjophthalmol-2014-305131"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305131","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,1]]}}}